The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis

Junjun Lu1,*
He Li2,*
Peng Guo1
Rui Shen3
Yingbin Luo1
Qiao Ge4
Wenfei Shi1
Yan Li1
Weikang Zhu1

1Department of Tumor, Shanghai Municipal Hospital of Traditional Chinese Medicine, 2Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, 3Department of Function, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 4Department of Tumor, Ninghai Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang, China

*These authors contributed equally to this work

Objective: To evaluate the effect of CYP2D6 *10 polymorphism (C 100C>T, rs1065852) on clinical outcomes of female Asian breast cancer patients with tamoxifen adjuvant treatment.

Methods: Meta-analysis of retrospective cohort studies published in July 2017 was performed. Fifteen studies with 1,794 Asian breast cancer patients were included, using strict eligibility requirements. Associations of disease-free survival (DFS), overall survival (OS) and recurrence rate after tamoxifen intake, with CYP2D6 *10 polymorphism were investigated through random effects models.

Results: CYP2D6 *10 polymorphism was found to have effect on DFS and recurrence rate in various comparison models, but not on overall survival in the female Asian breast cancer patients.

Conclusion: In conclusion, our meta-analysis suggests that significant association of *10/*10 (TT) genotype with poorer DFS and recurrence exists in female Asian breast cancer patients with tamoxifen 20 mg/day adjuvant treatment. In the future, large and well-designed studies are required to illustrate the interactions of CYP2D6 genetic variants, including *10 polymorphism and tamoxifen response on female breast cancer patients.

Keywords: CYP2D6 *10, polymorphism, breast cancer, Asia, tamoxifen adjuvant treatment

Introduction
Tamoxifen has been widely used for >30 years as adjuvant treatment for women operated for estrogen receptor-positive breast cancer. It is reported that postoperative 5-year tamoxifen therapy effectively reduces the risk of breast cancer recurrence by 39%1 and breast cancer mortality.1

The clinical efficacy of tamoxifen adjuvant treatment varies among individuals. Tamoxifen itself has weak affinity for the estrogen receptor and undergoes considerable first-pass oxidative metabolism to more potent metabolites, such as 4-hydroxytamoxifen and 4-hydroxy-N-desmethyl tamoxifen (endoxifen), which is the main active tamoxifen, and has up to a 33-fold higher affinity for the estrogen receptor than tamoxifen itself.2 The rate-limiting step in tamoxifen metabolism is mediated primarily by the highly polymorphic CYP2D6.3

Several studies have reported that CYP2D6 genetic mutations leading to the absence of functional enzyme are related to the decrease in 4-hydroxytamoxifen and endoxifen levels.4 However, it is still highly controversial on the clinical association of CYP2D6 genetic variants as predictors of tamoxifen efficacy at the standard dose of 20 mg/day. Nonfunctional allele variants of CYP2D6 gene were reported to be associated with increased risk of breast cancer relapse in female breast cancer patients4–8 and increased...
risk of breast cancer occurrence in unaffected women. Meanwhile, other studies do not support such an association.\textsuperscript{10–13} The causes of these conflicting results might be clarified by some newly emerged evidence,\textsuperscript{14,15} such as inclusion criteria for patients, source of deoxyribonucleic acid and genotyping method, coverage of genetic mutations and polymorphisms, as well as serological concentrations of endoxifen.

The classical CYP2D6-predicted phenotype is commonly divided into 4 levels of enzyme activity: poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers and ultrarapid metabolizers.\textsuperscript{16} To date, more than 100 allelic variants have been described for CYP2D6 gene.\textsuperscript{17} CYP2D6 *10 is a major variant and produces an unstable CYP2D6 enzyme, with an allele frequency of \(~50\%\) in Asians\textsuperscript{18} but only 2\% in Caucasians.\textsuperscript{19} Mutation of CYP2D6 *10 generates a 188 C to T transition in exon 1, leading to a Proline 34 to Serine amino acid substitution and resulting in an unstable enzyme with lower activity and metabolic conversion rate.\textsuperscript{20}

It would be of great interest to investigate whether CYP2D6 *10 genotype affects the efficacy of tamoxifen in female Asian breast cancer patients. To test this hypothesis, we investigated whether the CYP2D6 *10 genotype is associated with the clinical outcome in a particular population subgroup of female Asian breast cancer patients by meta-analysis.

Methods

Literature and search strategy

The PubMed, MEDLINE, Cochrane, Embase, Wan Fang and Chinese National Knowledge Infrastructure database searches were conducted for all the pertinent trials. The search terms were: “CYP2D6” and “polymorphism” and “tamoxifen” and “breast cancer”. Manual scrutiny for eligible articles was conducted according to the bibliography of the original and review reports. The literature search was updated in July 2017.

Study selection

Retrieved studies were deemed eligible provided that they met all the following criteria: 1) studies on human beings; 2) in a cohort design or randomized controlled trial design; 3) investigated the effect of CYP2D6 *10 polymorphism with outcome of breast cancer patients taking tamoxifen; 4) in Asian population; 5) treated with 20 mg/day adjuvant tamoxifen for 2–5 years; 6) detailed outcomes could be obtained or calculated on the outcome of disease-free survival (DFS), overall survival (OS) or recurrence rate; 7) the number of women with breast cancer was \(>30\); 8) and received more than 4 points in the Newcastle–Ottawa Scale (NOS), which was considered to be of high quality.

Data extraction

Three reviewers screened titles and abstracts for relevance to the topic independently (Junjun Lu, He Li and Peng Guo). All potential publications were independently evaluated in full text. The following information was sought for reaching consensus on all of the items: the first author’s name, year of publication, design of trial, comparison, number of patients, and the endpoints of clinical prognosis. Any disagreements were resolved by the fourth investigator (Zhu Weikang).

Statistical analysis

Five genic comparison models (TT vs CC, CT vs CC, TT vs CT/CC, TT/CT vs CC, and TT vs CT) for 3 endpoints (DFS, OS and reference) were analyzed. A \(\chi^2\)-test based on the Q test and \(I^2\) metric were used to quantify the heterogeneity.\textsuperscript{21} When \(I^2\)\textsuperscript{2}\textsuperscript{p}<0.1, the between-study heterogeneity was considered to be significant and the random-effects model was used. Otherwise, for homogeneous studies, the fixed effects model was used. The mean hazard ratios (HRs) and 95\% CIs were obtained from the original article by using survival analysis.\textsuperscript{22,23} If a publication did not provide HR values, Engauge Digitizer version 4.1 was used to obtain the HR values and 95\% CIs.\textsuperscript{24} The pooled HR was initially demonstrated using forest plots graphically. Begg’s Funnel plot and Egger’s test were conducted to evaluate the potential publication bias.\textsuperscript{24} Sensitivity analysis was performed to assess the stability of our outcomes by omitting each study sequentially. Hardy–Weinberg equilibrium was examined with goodness-of-fit \(\chi^2\)-test. Two-sided \(p<0.05\) was considered to be statistically significant. STATA version 12.0 (StataCorp LLC, College Station, TX, USA) was used for all the data analyses and graphs.

Results

Characteristics of studies included in this meta-analysis

Initial search yielded a total of 221 potentially relevant citations. Finally, 15 studies\textsuperscript{7,25–38} were included in our meta-analysis to meet the inclusion criteria (Figure 1). Publication years ranged from January 2008 to July 2017; the number of breast cancer patients varied from 39 to 296 (Table 1). As a result, data for our meta-analysis were available from 15 studies with a total of 1,794 Asian breast cancer patients. The eligible studies were assessed by the NOS. Each of the
CYP2D6 *10 polymorphism effect on DFS studies scored >4, which suggested that all the research was of high quality (Table 1).

Meta-analysis results

The pooled effect of CYP2D6 *10 genotype on the DFS of breast cancer patients treated with tamoxifen is shown in Figure 2 and Table 2. CYP2D6 *10 polymorphism (C100C>T, rs1065852) significantly influences DFS in various comparison models (TT vs CC: HR = 1.79, 95% CI = 1.14–2.80, p = 0.011; CT vs CC: HR = 2.02, 95% CI = 1.04–3.91, p = 0.037; TT vs CC: HR = 1.79, 95% CI = 1.14–2.80, p = 0.011; TT vs CT: HR = 2.03, 95% CI = 1.41–2.93, p < 0.001; TT vs CT/CC: HR = 2.19, 95% CI = 1.07–4.50, p = 0.033) except the dominant model (TT/CT vs CC: HR = 1.80, 95% CI = 0.81–4.00, p = 0.147).

Heterogeneity

There was no significant between-study heterogeneity for the endpoint of DFS in the comparison model of TT vs CC ($I^2 = 44.5\%$, $p = 0.114$), CT vs CC ($I^2 = 36.3\%$, $p = 0.194$) and

Table 1 Characteristics and quality assessment of the included studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Country</th>
<th>Sample size</th>
<th>Menopause status (pre + post)</th>
<th>Follow-up (months)*</th>
<th>Endpoints</th>
<th>Genotyping method</th>
<th>HWE</th>
<th>NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xu et al</td>
<td>China</td>
<td>152</td>
<td>–</td>
<td>63 (4–122)</td>
<td>DFS</td>
<td>RT-PCR</td>
<td>Y</td>
<td>6</td>
</tr>
<tr>
<td>Kiyotani et al</td>
<td>Japan</td>
<td>67</td>
<td>35+32</td>
<td>96 (19.2–259.2)</td>
<td>RFS, recurrence</td>
<td>TaqMan</td>
<td>Y</td>
<td>7</td>
</tr>
<tr>
<td>Sirachainan et al</td>
<td>Thailand</td>
<td>39</td>
<td>31+8</td>
<td>52.3–97.4</td>
<td>DFS</td>
<td>Pyrosequencing</td>
<td>Y</td>
<td>6</td>
</tr>
<tr>
<td>Sukasem et al</td>
<td>Thailand</td>
<td>48</td>
<td>30+18</td>
<td>67.2</td>
<td>DFS</td>
<td>Microarray</td>
<td>Y</td>
<td>7</td>
</tr>
<tr>
<td>Teh et al</td>
<td>Mixed*</td>
<td>95</td>
<td>33+62</td>
<td>–</td>
<td>–</td>
<td>TaqMan</td>
<td>Y</td>
<td>7</td>
</tr>
<tr>
<td>Chamnanphon et al</td>
<td>Thailand</td>
<td>57</td>
<td>38+19</td>
<td>48 (2–172)</td>
<td>DFS, recurrence</td>
<td>Microarray</td>
<td>Y</td>
<td>6</td>
</tr>
<tr>
<td>Tian et al</td>
<td>China</td>
<td>200</td>
<td>–</td>
<td>31.8 (9–58)</td>
<td>DFS</td>
<td>TaqMan</td>
<td>Y</td>
<td>7</td>
</tr>
<tr>
<td>Wei and Xu</td>
<td>China</td>
<td>257</td>
<td>–</td>
<td>35 (12–43)</td>
<td>DFS, OS</td>
<td>RT-PCR</td>
<td>Y</td>
<td>5</td>
</tr>
<tr>
<td>Xiao et al</td>
<td>China</td>
<td>87</td>
<td>0+87</td>
<td>60</td>
<td>OS</td>
<td>RT-PCR</td>
<td>Y</td>
<td>5</td>
</tr>
<tr>
<td>Wang et al</td>
<td>China</td>
<td>171</td>
<td>–</td>
<td>30.5 (5–40)</td>
<td>Recurrence</td>
<td>RT-PCR</td>
<td>Y</td>
<td>5</td>
</tr>
<tr>
<td>Zhang et al</td>
<td>China</td>
<td>296</td>
<td>174+122</td>
<td>–</td>
<td>OS</td>
<td>Sequencing*</td>
<td>*</td>
<td>6</td>
</tr>
<tr>
<td>Lei et al</td>
<td>China</td>
<td>72</td>
<td>65+7</td>
<td>85 (20–144)</td>
<td>DFS, OS</td>
<td>Pyrosequencing</td>
<td>Y</td>
<td>6</td>
</tr>
<tr>
<td>Sensorn et al</td>
<td>Thailand</td>
<td>73</td>
<td>47+26</td>
<td>87.6 (60–171.6)</td>
<td>DFS</td>
<td>RT-PCR</td>
<td>Y</td>
<td>7</td>
</tr>
<tr>
<td>Yu et al</td>
<td>China</td>
<td>106</td>
<td>–</td>
<td>–</td>
<td>DFS</td>
<td>RT-PCR</td>
<td>Y</td>
<td>5</td>
</tr>
<tr>
<td>Zeng et al</td>
<td>China</td>
<td>76</td>
<td>–</td>
<td>30.5 (5–40)</td>
<td>Recurrence, OS</td>
<td>RT-PCR</td>
<td>Y</td>
<td>5</td>
</tr>
</tbody>
</table>

Notes: *Mixed includes patients in Malaysia, China, and India. **HWE of Zhang et al was unknown and could not be estimated. *Data presented as median (range).

Abbreviations: DFS, disease-free survival; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle–Ottawa scale; OS, overall survival; RFS, relapse-free survival; RT-PCR, real-time-polymerase chain reaction.
TT vs CT \( (I^2=0\%, p=0.958) \). Meanwhile, for the dominant model and recessive model, heterogeneity was detected to be significant. Thus, random-effects estimates would be more appropriate for data analysis. Similarly, the random-effect model was conducted for the comparison of TT vs CC for OS and T allele vs C allele for recurrence (Tables 3 and 4).

### Table 2

Results of the effect of CYP2D6 *10 polymorphism on the DFS of breast cancer patients taking tamoxifen

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Studies</th>
<th>Overall effect</th>
<th>Heterogeneity</th>
<th>Publication bias</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>Z p-value</td>
<td>P, % p-value</td>
</tr>
<tr>
<td>TT vs CC</td>
<td>4</td>
<td>1.79 (1.14–2.80)</td>
<td>2.54 0.011</td>
<td>44.50 0.144</td>
</tr>
<tr>
<td>CT vs CC</td>
<td>4</td>
<td>2.02 (1.04–3.91)</td>
<td>2.09 0.037</td>
<td>36.30 0.194</td>
</tr>
<tr>
<td>TT vs CT/CC</td>
<td>4</td>
<td>2.19 (1.07–4.50)</td>
<td>2.13 0.033</td>
<td>52.60 0.097</td>
</tr>
<tr>
<td>TT/CT vs CC</td>
<td>2</td>
<td>1.80 (0.81–4.00)</td>
<td>1.45 0.147</td>
<td>53.00 0.145</td>
</tr>
<tr>
<td>TT vs CT</td>
<td>2</td>
<td>2.03 (1.41–2.93)</td>
<td>3.79 0.000</td>
<td>95.98</td>
</tr>
</tbody>
</table>

**Notes:** Different from DFS, the pooled results of the endpoint of OS showed that there was no relationship between CYP2D6 *10 polymorphism and OS of female breast cancer patients with adjuvant tamoxifen. As shown in Table 3, all the genetic models did not support any evidence of association (TT vs CC: HR = 1.05, 95% CI = 0.35–3.11, p=0.934; CT vs CC: HR = 1.29, 95% CI = 0.83–2.00, p=0.225; TT vs CT/CC: HR = 0.96, 95% CI = 0.62–1.48, p=0.858; TT/CT vs CC: HR = 1.57, 95% CI = 0.89–2.77, p=0.119). For the additive comparison model of TT vs CT, which was reported by only one study, the result was negative as well.

**Abbreviations:** DFS, disease-free survival; HR, hazard ratio; OS, overall survival.

### Publication bias and sensitivity analysis

The publication bias of literature was assessed with both funnel plots and Egger’s test. As shown in Tables 2–4, our results did not reveal any obvious asymmetry in the funnel plots. Moreover, the Egger’s test, which was used to provide statistical evidence of publication bias, suggested
that no evidence of publication bias existed in the overall analysis ($p > 0.05$ for all the comparisons). Sensitivity analyses showed that omitting each individual study from all the analyses did not affect the pooled odds ratios significantly, and no substantial change was detected, indicating that our results were statistically robust (Figure 5).

**Discussion**

The CYP2D6 gene has earned special attention because an increasing number of studies have revealed that polymorphisms of the CYP2D6 gene were associated with the outcomes following tamoxifen treatment for breast cancer.\(^{10}\) However, the results across studies have been equivocal.\(^{20,41}\) Previous meta-analyses were performed by Jung and Lim,\(^{17}\) Province et al\(^{12}\) and Johansson et al.\(^{45}\) These meta-analyses were designed to evaluate the effect of CYP2D6 metabolizer types on outcome of breast cancer patients with tamoxifen treatment, for all the ethnicities. Different from these previous studies, our investigation aimed to assess the effect in a certain population and for a certain polymorphism, and was conducted in Asian breast cancer patients for CYP2D6 *10 polymorphism. Therefore, to our knowledge, it would be the first meta-analysis to report the unique association between CYP2D6 *10 and efficacy of tamoxifen in Asian breast cancer patients.

Ethnic difference in genetic background is one of the most important biological factors that might influence the patients’ clinical response and efficacy.\(^{44}\) CYP2D6 *10 variant is commonly reported in Asian population, but not in other ethnicities.\(^{19}\) The genetic discrepancies might be one of the reasons for the dispute on effect of CYP2D6 variants on tamoxifen response. Besides, the coverage of CYP2D6 mutations in the different studies might also play a role in the dispute.\(^{20}\) Most research studies reported CYP2D6 metabolizer types with their effect of tamoxifen efficacy, however, CYP2D6-predicted phenotype classified system was too variable to reach a consensus. Therefore, it is of great clinical significance to conduct this meta-analysis to reveal the effect of CYP2D6 *10 polymorphism on the tamoxifen efficacy in Asian patients. It might provide a new insight on a range of outcomes, investigating a potential gene dose-response relationship, and an assessment of data from trials that investigated effect modification of tamoxifen by CYP2D6 genotype status.

In the process of study inclusion, we selected several indicators, including DFS, OS, and recurrence rate as the endpoints of our meta-analysis. These indicators were commonly reported by various studies and were suitable to be pooled. In fact, 2 of the studies included\(^{26,41}\) reported the outcome of relapse-free survival (RFS). However, we failed to pool the results of RFS because these studies were with a different genetic comparison model. Similarly, data of disease-specific survival, time to progression, recurrence-free time were also reported by some studies but not available to be pooled.

### Table 3 Results of the effect of CYP2D6 *10 polymorphism on the OS of female breast cancer patients taking tamoxifen

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Studies</th>
<th>Overall effect</th>
<th>Heterogeneity</th>
<th>Publication bias</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>$p$-value</td>
<td>$I^2$, %</td>
</tr>
<tr>
<td>TT vs CC</td>
<td>3</td>
<td>1.05 (0.35–3.11)</td>
<td>0.08</td>
<td>0.934</td>
</tr>
<tr>
<td>CT vs CC</td>
<td>3</td>
<td>1.29 (0.83–2.00)</td>
<td>1.14</td>
<td>0.255</td>
</tr>
<tr>
<td>TT vs CT/CC</td>
<td>2</td>
<td>0.96 (0.62–1.48)</td>
<td>0.18</td>
<td>0.858</td>
</tr>
<tr>
<td>TT/CT vs CC</td>
<td>2</td>
<td>1.57 (0.89–2.77)</td>
<td>1.56</td>
<td>0.119</td>
</tr>
<tr>
<td>TT vs CT</td>
<td>1</td>
<td>1.36 (0.58–3.18)</td>
<td>0.71</td>
<td>0.478</td>
</tr>
</tbody>
</table>

**Notes:** The results of the endpoint of recurrence are shown in Figure 3 and Table 4. CYP2D6 *10 polymorphism was found to be associated with the increased risk of relapse of breast cancer in different genetic models (TT vs CC: OR = 4.07, 95% CI = 1.88–8.80, $p = 0.001$; TT vs CT/CC: OR = 3.69, 95% CI = 2.13–6.41, $p < 0.001$; TT/CT vs CC: 2.52, 95% CI = 1.24–5.13, $p = 0.011$; T allele vs C allele: 2.99, 95% CI = 1.46–6.11, $p = 0.029$). However, in the heterozygous model, heterozygous variant of CYP2D6 *10 gene did not increase the risk of relapse (CT vs CC: OR = 1.39, 95% CI = 0.62–3.13, $p = 0.427$).

**Abbreviations:** HR, hazard ratio; OS, overall survival.

### Table 4 Results of the effect of CYP2D6 *10 polymorphism on the recurrence of breast cancer in patients taking tamoxifen

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Overall effect</th>
<th>Heterogeneity</th>
<th>Publication bias</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>$p$-value</td>
<td>$I^2$, %</td>
</tr>
<tr>
<td>TT vs CC</td>
<td>4.07 (1.88–8.80)</td>
<td>3.57</td>
<td>0</td>
</tr>
<tr>
<td>CT vs CC</td>
<td>1.39 (0.62–3.13)</td>
<td>0.79</td>
<td>0.427</td>
</tr>
<tr>
<td>TT vs CT/CC</td>
<td>3.69 (2.13–6.41)</td>
<td>4.65</td>
<td>0</td>
</tr>
<tr>
<td>TT/CT vs CC</td>
<td>2.52 (1.24–5.13)</td>
<td>2.55</td>
<td>0.011</td>
</tr>
<tr>
<td>T vs C*</td>
<td>2.99 (1.46–6.11)</td>
<td>3</td>
<td>0.003</td>
</tr>
</tbody>
</table>

**Note:** Random effects model was used for the comparison of allele genetic model as heterogeneity is significant.

**Abbreviation:** OR, odds ratio.
Tamoxifen will still be commonly used in both premenopausal and postmenopausal women in the foreseeable future. Therefore, analysis of \textit{CYP2D6} *10 genotype may be useful in identifying patients who are more likely to benefit from tamoxifen treatment. In fact, men with breast cancer are also an important subgroup who are treated in adjuvant setting preferentially with tamoxifen. \textit{CYP2D6} *4 polymorphism was reported to be associated with a probability of recurrence in male breast cancer.\textsuperscript{46} Therefore, analysis of \textit{CYP2D6} *10 variant in male breast cancer would also be of great clinical significance. Our meta-analysis indicated the relationship of \textit{CYP2D6} *10 polymorphism with tamoxifen response existed both on the endpoints of DFS and recurrence rate in female Asian breast cancer patients, with tamoxifen 20 mg/day adjuvant therapy. It is consistent in direction with the hypothesis that reduced tamoxifen metabolism is associated with poorer outcome.\textsuperscript{5,11,30}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Forest plot to estimate the effect of \textit{CYP2D6} *10 polymorphism on the recurrence of breast cancer in patients taking tamoxifen in the comparison of (A) TT vs CC; (B) CT/TT vs CC; (C) TT vs CT/TT and (D) T vs C allele. \textbf{Note:} Weights are from random effects analysis. \textbf{Abbreviations:} CI, confidence interval; OR, odds ratio.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{Begg's funnel plots to examine publication bias for reported comparisons of \textit{CYP2D6} *10 polymorphism with recurrence in the comparison of (A) CT vs CC and (B) TT vs CC in Asian breast cancer patients treated with tamoxifen. \textbf{Abbreviations:} OR, odds ratio; SE, standard error.}
\end{figure}
tamoxifen efficacy. The former might be invalid, because this comparison contains only 2 studies, with significant heterogeneity ($I^2=53\%, p=0.145$), and is in contradiction to the other comparison, especially in TT vs CC and CT vs CC. For the CT vs CC comparison in recurrence, the results are without any between-study heterogeneity, and considered to be reliable. Our results suggests the decrease in enzyme activity caused by heterozygous mutation of CYP2D6 *10 does not translate into a significant poorer clinical outcome. Meanwhile, CYP2D6 *10 polymorphism was not associated with OS after pooled analysis, which was not consistent with the hypothesis. Given that OS is defined as the time from randomization to all-cause mortality, which is different from DFS, it might include in some death records that is irrelevant to cancer. Besides, for the endpoint of OS, 3 studies and 2 studies were pooled in different comparisons, which is relatively few and may have underpowered the results.

The heterogeneity between the studies was very low in our analysis. This suggested that the results from these studies were suitable to be pooled. The sensitivity analysis indicated that studies contributing to the heterogeneity did not significantly alter the pooled results. This suggested that our results were statistically robust. Taken together, our results might provide insights into the individualized therapy of breast cancer patients.

In summary, our meta-analysis might be the first meta-analysis to estimate the association of CYP2D6 *10 polymorphism with the efficacy of tamoxifen treatment in female Asian breast cancer patients. Significant association of *10/*10 (TT) genotype with poorer DFS and recurrence was found in the Asian population. In the future, large and well-designed studies are required to illustrate the interactions of CYP2D6 genetic variants, including *10 polymorphism and tamoxifen response in female breast cancer patients.

Acknowledgment
The studies included obtained informed consent from all individual participants included in these studies.

Disclosure
The authors report no conflicts of interest in this work.

References


